Serum Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) as a Potential Biomarker for Diagnosis of Hepatocellular Carcinoma

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Inst. 2022;2(1):1–9. doi:10.1016/j.jncc.2022.02.002
   Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. doi:10.1038/nrdp.2016.18
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing. Future Oncol. 2020;16(32):2587–2589. doi:10.2217/fon-2020-0669
   PubMed Web of Science ®Google Scholar
• Mollica V, Rizzo A, Marchetti A, et al. The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study. Clin Exp Med. 2023;23(8):5039–5049. doi:10.1007/s10238-023-01159-1
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Trans-arterial chemoembolization plus systemic treatments for hepatocellular carcinoma: an update. J Pers Med. 2022;12(11):1788. doi:10.3390/jpm12111788
   PubMed Web of Science ®Google Scholar
• Santoni M, Rizzo A, Mollica V, et al. The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study. Crit Rev Oncol Hematol. 2022;170:103596. doi:10.1016/j.critrevonc.2022.103596
   PubMed Web of Science ®Google Scholar
• Lu Q, Li J, Cao H, Lv C, Wang X, Cao S. Comparison of diagnostic accuracy of midkine and AFP for detecting hepatocellular carcinoma: a systematic review and meta-analysis. Biosci Rep. 2020;40(3). doi:10.1042/bsr20192424
   Google Scholar
• Ye X, Li C, Zu X, et al. A large-scale multicenter study validates aldo-keto reductase family 1 member B10 as a prevalent serum marker for detection of hepatocellular carcinoma. Hepatology. 2019;69(6):2489–2501. doi:10.1002/hep.30519
   PubMed Web of Science ®Google Scholar
• Ye Q, Ling S, Zheng S, Xu X. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer. 2019;18(1):114. doi:10.1186/s12943-019-1043-x
   PubMed Web of Science ®Google Scholar
• Cao D, Fan ST, Chung SS. Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem. 1998;273(19):11429–11435. doi:10.1074/jbc.273.19.11429
   PubMed Web of Science ®Google Scholar
• Zhong L, Liu Z, Yan R, et al. Aldo-keto reductase family 1 B10 protein detoxifies dietary and lipid-derived alpha, beta-unsaturated carbonyls at physiological levels. Biochem Biophys Res Commun. 2009;387(2):245–250. doi:10.1016/j.bbrc.2009.06.123
   PubMed Web of Science ®Google Scholar
• Gallego O, Ruiz FX, Ardèvol A, et al. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci U S A. 2007;104(52):20764–20769. doi:10.1073/pnas.0705659105
   PubMed Web of Science ®Google Scholar
• Zhu R, Xiao J, Luo D, Dong M, Sun T, Jin J. Serum AKR1B10 predicts the risk of hepatocellular carcinoma - a retrospective single-center study. Gastroenterol Hepatol. 2019;42(10):614–621. doi:10.1016/j.gastrohep.2019.06.007
   PubMed Web of Science ®Google Scholar
• Murata A, Genda T, Ichida T, et al. Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication. World J Gastroenterol. 2016;22(33):7569–7578. doi:10.3748/wjg.v22.i33.7569
   PubMed Web of Science ®Google Scholar
• Matkowskyj KA, Bai H, Liao J, et al. Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions. Hum Pathol. 2014;45(4):834–843. doi:10.1016/j.humpath.2013.12.002
   PubMed Web of Science ®Google Scholar
• Xie C, Ye X, Zeng L, Zeng X, Cao D. Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma. J Gastroenterol. 2023;58(10):1030–1042. doi:10.1007/s00535-023-02011-9
   PubMed Web of Science ®Google Scholar
• Han C, Gao L, Bai H, Dou X. Identification of a role for serum aldo-keto reductase family 1 member B10 in early detection of hepatocellular carcinoma. Oncol Lett. 2018;16(6):7123–7130. doi:10.3892/ol.2018.9547
   PubMed Web of Science ®Google Scholar
• Han C, Gao L, Zhao L, et al. Immunohistochemistry detects increased expression of aldo-keto reductase family 1 member B10 (AKR1B10) in early-stage hepatocellular carcinoma. Med Sci Monit. 2018;24:7414–7423. doi:10.12659/msm.910738
   PubMed Web of Science ®Google Scholar
• Schmitz KJ, Sotiropoulos GC, Baba HA, et al. AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases. Liver Int. 2011;31(6):810–816. doi:10.1111/j.1478-3231.2011.02511.x
   PubMed Web of Science ®Google Scholar
• Ha SY, Song DH, Lee JJ, Lee HW, Cho SY, Park CK. High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma. Gut Liver. 2014;8(6):648–654. doi:10.5009/gnl13406
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition). Liver Cancer. 2018;7(3):235–260. doi:10.1159/000488035
   PubMed Web of Science ®Google Scholar
• Wu CY, Jan YJ, Ko BS, Wu YJ, Wu YJ, Liou JY. Prognostic significance of 14-3-3ε, aldo-keto reductase family 1 B10 and metallothionein-1 in Hepatocellular carcinoma. Anticancer Res. 2018;38(12):6855–6863. doi:10.21873/anticanres.13060
   PubMed Web of Science ®Google Scholar
• Tsuzura H, Genda T, Sato S, et al. Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis. Int J Mol Sci. 2014;15(4):6556–6568. doi:10.3390/ijms15046556
   PubMed Web of Science ®Google Scholar
• Sonohara F, Inokawa Y, Hishida M, et al. Prognostic significance of AKR1B10 gene expression in hepatocellular carcinoma and surrounding non-tumorous liver tissue. Oncol Lett. 2016;12(6):4821–4828. doi:10.3892/ol.2016.5240
   PubMed Web of Science ®Google Scholar
• Torres-Mena JE, Salazar-Villegas KN, Sánchez-Rodríguez R, et al. Aldo-keto reductases as early biomarkers of Hepatocellular carcinoma: a comparison between animal models and human HCC. Dig Dis Sci. 2018;63(4):934–944. doi:10.1007/s10620-018-4943-5
   PubMed Web of Science ®Google Scholar
• Liu Z, Yan R, Al-Salman A, et al. Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells. Biochem J. 2012;442(2):273–282. doi:10.1042/bj20111322
   PubMedGoogle Scholar
• Zhang T, Guan G, Zhang J, et al. E2F1-mediated AUF1 upregulation promotes HCC development and enhances drug resistance via stabilization of AKR1B10. Cancer Sci. 2022;113(4):1154–1167. doi:10.1111/cas.15272
   PubMed Web of Science ®Google Scholar
• Wang Z, Pei Y, Li W, Zhang J, Liu J, Abdel Ghafar MT. Clinical value of AKR1B10 in hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2022;17(12):e0279591. doi:10.1371/journal.pone.0279591
   PubMed Web of Science ®Google Scholar
• Xu D, Su C, Sun L, Gao Y, Li Y. Performance of serum glypican 3 in diagnosis of Hepatocellular carcinoma: a meta-analysis. Ann Hepatol. 2019;18(1):58–67. doi:10.5604/01.3001.0012.7863
   PubMed Web of Science ®Google Scholar
• Pang BY, Leng Y, Wang X, Wang YQ, Jiang LH. A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma. Ann Med. 2023;55(1):42–61. doi:10.1080/07853890.2022.2153163
   PubMed Web of Science ®Google Scholar
• Liu Z, Pu Y, Bao Y, He S. Investigation of potential molecular biomarkers for diagnosis and prognosis of AFP-negative HCC. Int J Gen Med. 2021;14:4369–4380. doi:10.2147/ijgm.S323868
   PubMed Web of Science ®Google Scholar
• Lu Z, Priya Rajan SA, Song Q, et al. 3D scaffold-free microlivers with drug metabolic function generated by lineage-reprogrammed hepatocytes from human fibroblasts. Biomaterials. 2021;269:120668. doi:10.1016/j.biomaterials.2021.120668
   PubMed Web of Science ®Google Scholar
• Triozzi PL, Stirling ER, Song Q, et al. Circulating immune bioenergetic, metabolic, and genetic signatures predict melanoma patients’ response to anti-PD-1 immune checkpoint blockade. Clin Cancer Res. 2022;28(6):1192–1202. doi:10.1158/1078-0432.Ccr-21-3114
   PubMed Web of Science ®Google Scholar